✦ LIBER ✦

Everolimus plus exemestane as first-line therapy in HR+, HER2−advanced breast cancer in BOLERO-2

✍ Scribed by Beck, J. Thaddeus; Hortobagyi, Gabriel N.; Campone, Mario; Lebrun, Fabienne; Deleu, Ines; Rugo, Hope S.; Pistilli, Barbara; Masuda, Norikazu; Hart, Lowell; Melichar, Bohuslav; Dakhil, Shaker; Geberth, Matthias; Nunzi, Martina; Heng, Daniel Y. C.; Brechenmacher, Thomas; El-Hashimy, Mona; Douma, Shyanne; Ringeisen, Francois; Piccart, Martine

Book ID: 121489366
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 341 KB
Volume: 143
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-013-2814-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Everolimus Plus Exemestane in Postmenopa

Everolimus Plus Exemestane in Postmenopausal Patients with HR+Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

✍ Yardley, Denise A.; Noguchi, Shinzaburo; Pritchard, Kathleen I.; Burris, Howard 📂 Article 📅 2013 🏛 Springer Healthcare Communications 🌐 English ⚖ 505 KB

1LBA Everolimus plus exemestane for horm

1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2

✍ Piccart, M.; Hortobagyi, G.N.; Campone, M.; Pritchard, K.I.; Noguchi, S.; Rugo, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 46 KB

PO59 EFFICACY AND SAFETY OF EVEROLIMUS P

PO59 EFFICACY AND SAFETY OF EVEROLIMUS PLUS EXEMESTANE COMBINATION THERAPY VERSUS MONOTHERAPY WITH EVEROLIMUS OR CAPECITABINE IN HR+, HER2− BREAST CANCER: A MULTI-CENTER, OPEN-LABEL, PHASE 2 TRIAL BOLERO-6

✍ de Boer, Richard; Jerusalem, Guy; Hurvitz, Sara; Ejlertsen, Bent; El-Hashimy, Mo 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Efficacy of everolimus with exemestane v

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

✍ Noguchi, Shinzaburo; Masuda, Norikazu; Iwata, Hiroji; Mukai, Hirofumi; Horiguchi 📂 Article 📅 2013 🏛 Springer Japan 🌐 English ⚖ 662 KB

5075 Sunitinib plus docetaxel and trastu

5075 Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer

✍ F. Cardoso; J.L. Canon; D. Amadori; L. Dirix; E. Villa; D. Aldrighetti; J.P. Mac 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Safety and Efficacy of Everolimus With E

Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2

✍ Pritchard, Kathleen I.; Burris, Howard A.; Ito, Yoshinori; Rugo, Hope S.; Dakhil 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 782 KB